Phase I and Clinical Pharmacology Citations 1-25 of 152 total displayed. Immunotherapy Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Adil I. Daud, Ronald C. DeConti, Stephanie Andrews, Patricia Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Munster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, and Richard Heller J. Clin. Oncol. 2008; 26: 5896-5903. [Abstract] [Full text] [PDF]   Immunotherapy Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Adil I. Daud, Ronald C. DeConti, Stephanie Andrews, Patricia Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Munster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, and Richard Heller J. Clin. Oncol. 2008; 26: 5896-5903. [Abstract] [Full text] [PDF]   Commentary Retinol, Vitamins, and Cancer Prevention: 25 Years of Learning and Relearning Gary E. Goodman, David S. Alberts, and Frank L. Meyskens J. Clin. Oncol. 2008; 26: 5495-5496. [Full text] [PDF]   Editorials Targeting Polo-Like Kinase: Learning Too Little Too Late? David Olmos, Charles Swanton, and Johann de Bono J. Clin. Oncol. 2008; 26: 5497-5499. [Full text] [PDF]   Phase I and Clinical Pharmacology Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors Antonio Jimeno, Jing Li, Wells A. Messersmith, Daniel Laheru, Michelle A. Rudek, Manoj Maniar, Manuel Hidalgo, Sharyn D. Baker, and Ross C. Donehower J. Clin. Oncol. 2008; 26: 5504-5510. [Abstract] [Full text] [PDF]   Phase I and Clinical Pharmacology Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors Klaus Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Jochen Rentschler, Rolf Kaiser, Nicolas Rouyrre, Dirk Trommeshauser, Cornelia E. Hoesl, and Gerd Munzert J. Clin. Oncol. 2008; 26: 5511-5517. [Abstract] [Full text] [PDF]   Immunotherapy Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Adil I. Daud, Ronald C. DeConti, Stephanie Andrews, Patricia Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Munster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, and Richard Heller J. Clin. Oncol. 10.1200/JCO.2007.15.6794. [Abstract] [PDF]   Commentary High-Dose Etoposide: From Phase I to a Component of Curative Therapy Steven N. Wolff, John D. Hainsworth, and F. Anthony Greco J. Clin. Oncol. 2008; 26: 5310-5312. [Full text] [PDF]   Editorials Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run Elisabeth G.E. de Vries and Steven de Jong J. Clin. Oncol. 2008; 26: 5151-5153. [Full text] [PDF]   Phase I and Clinical Pharmacology Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin Anthony W. Tolcher, Alain Mita, Lionel D. Lewis, Christopher R. Garrett, Elizabeth Till, Adil I. Daud, Amita Patnaik, Kyri Papadopoulos, Chris Takimoto, Pamela Bartels, Anne Keating, and Scott Antonia J. Clin. Oncol. 2008; 26: 5198-5203. [Abstract] [Full text] [PDF]   Commentary Retinol, Vitamins, and Cancer Prevention: 25 Years of Learning and Relearning Gary E. Goodman, David S. Alberts, and Frank L. Meyskens J. Clin. Oncol. 10.1200/JCO.2008.19.0884. [Abstract] [PDF]   Editorial Targeting Polo-Like Kinase: Learning Too Little Too Late? David Olmos, Charles Swanton, and Johann de Bono J. Clin. Oncol. 10.1200/JCO.2008.18.6585. [Abstract] [PDF]   Phase I and Clinical Pharmacology Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors Antonio Jimeno, Jing Li, Wells A. Messersmith, Daniel Laheru, Michelle A. Rudek, Manoj Maniar, Manuel Hidalgo, Sharyn D. Baker, and Ross C. Donehower J. Clin. Oncol. 10.1200/JCO.2008.17.9788. [Abstract] [PDF]   Phase I and Clinical Pharmacology Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors Klaus Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Jochen Rentschler, Rolf Kaiser, Nicolas Rouyrre, Dirk Trommeshauser, Cornelia E. Hoesl, and Gerd Munzert J. Clin. Oncol. 10.1200/JCO.2008.16.1547. [Abstract] [PDF]   Commentary High-Dose Etoposide: From Phase I to a Component of Curative Therapy Steven N. Wolff, John D. Hainsworth, and F. Anthony Greco J. Clin. Oncol. 10.1200/JCO.2008.19.0892. [Abstract] [PDF]   Genitourinary Cancer Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Gerhardt Attard, Alison H.M. Reid, Timothy A. Yap, Florence Raynaud, Mitch Dowsett, Sarah Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David Dearnaley, Gloria Lee, and Johann S. de Bono J. Clin. Oncol. 2008; 26: 4563-4571. [Abstract] [Full text] [PDF]   Editorials Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run Elisabeth G.E. de Vries and Steven de Jong J. Clin. Oncol. 10.1200/JCO.2008.18.3160. [Abstract] [PDF]   Phase I and Clinical Pharmacology Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin Anthony W. Tolcher, Alain Mita, Lionel D. Lewis, Christopher R. Garrett, Elizabeth Till, Adil I. Daud, Amita Patnaik, Kyri Papadopoulos, Chris Takimoto, Pamela Bartels, Anne Keating, and Scott Antonia J. Clin. Oncol. 10.1200/JCO.2008.17.2064. [Abstract] [PDF]   Phase I and Clinical Pharmacology Phase I Study of Adenovirus p53 Administered by Bronchoalveolar Lavage in Patients With Bronchioloalveolar Cell Lung Carcinoma: ECOG 6597 Vicki Keedy, Wei Wang, Joan Schiller, Sunil Chada, Bonnie Slovis, Keith Coffee, John Worrell, Lyn A. Thet, David H. Johnson, and David P. Carbone J. Clin. Oncol. 2008; 26: 4166-4171. [Abstract] [Full text] [PDF]   Phase I and Clinical Pharmacology Pharmacodynamic-Guided Modified Continuous Reassessment Method–Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors Antonio Jimeno, Michelle A. Rudek, Peter Kulesza, Wen Wee Ma, Jenna Wheelhouse, Anna Howard, Yasmin Khan, Ming Zhao, Heather Jacene, Wells A. Messersmith, Daniel Laheru, Ross C. Donehower, Elizabeth Garrett-Mayer, Sharyn D. Baker, and Manuel Hidalgo J. Clin. Oncol. 2008; 26: 4172-4179. [Abstract] [Full text] [PDF]   Clinical Research Performing Nondiagnostic Research Biopsies in Irradiated Tissue: A Review of Scientific, Clinical, and Ethical Considerations Aaron P. Brown, David S. Wendler, Kevin A. Camphausen, Franklin G. Miller, and Deborah Citrin J. Clin. Oncol. 2008; 26: 3987-3994. [Abstract] [Full text] [PDF]   Editorials Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies Stephen A. Cannistra J. Clin. Oncol. 2008; 26: 3665-3667. [Full text] [PDF]   Phase I and Clinical Pharmacology Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski, Seth M. Steinberg, Lokesh Jain, Christina M. Annunziata, Lori Minasian, Gisele Sarosy, Herbert L. Kotz, Ahalya Premkumar, Liang Cao, Deborah McNally, Catherine Chow, Helen X. Chen, John J. Wright, William D. Figg, and Elise C. Kohn J. Clin. Oncol. 2008; 26: 3709-3714. [Abstract] [Full text] [PDF]   Clinical Trials Phase II Stopping Rules That Employ Response Rates and Early Progression John R. Goffin and Dongsheng Tu J. Clin. Oncol. 2008; 26: 3715-3720. [Abstract] [Full text] [PDF]   Articles Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Gerhardt Attard, Alison H.M. Reid, Timothy A. Yap, Florence Raynaud, Mitch Dowsett, Sarah Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David Dearnaley, Gloria Lee, and Johann S. de Bono J. Clin. Oncol. 10.1200/JCO.2007.15.9749. [Abstract] [PDF]   Review Article Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL) Avi Ashkenazi, Pamela Holland, and S. Gail Eckhardt J. Clin. Oncol. 2008; 26: 3621-3630. [Abstract] [Full text] [PDF]   [Next page] Pages: 1 2 3 4 5 6 7